← Home / CytomX Therapeutics, Inc. (CTMX)
Stock Analysis
CytomX Therapeutics, Inc. (CTMX)
CTMX
CTMX · Market data
3.10 -5.49%
Track CTMX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CTMX price is:
52W Range Position
27%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 19:55 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
3.40
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
27
●
Management / Board
MEDIUM
CTMX board and management update
On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc.
8-K Filing • SEC EDGAR
JUN
3
●
Material Agreement
MEDIUM
CTMX material agreement
(the “Company”) previously entered into that certain Collaboration and License Agreement, effective November 16, 2022 (as amended, the “Agreement”), with Regeneron Pharmaceuticals, Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
CytomX Therapeutics Announces Q1 2026 Financial Results and Provides
(Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced Q1 2026 financial results and provided a business update.
8-K Filing • SEC EDGAR
What's Driving CTMX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 3.40 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
34.8
Price Chart
CTMX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$204.4M
Company size
EV
$178.6M
Debt-adjusted value
P/E
-11.8
Not meaningful
P/S
5.8
Balanced
P/B
0.6
Low book multiple
EV/Sales
5.0
Balanced
EV/EBIT
-8.0
Not meaningful
P/FCF
-2.5
Not meaningful
FCF Yield
-39.23%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
10.26M
↘ Weak
📈 Net Income
-18.25M
↘ Negative
CytomX Therapeutics, Inc.
Related Opportunities